Jazz Pharmaceuticals (JAZZ) vs Praxis Precision Medicines (PRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed Jazz Pharmaceuticals (JAZZ) over the past year, gaining 434.2% versus a gain of 68.4%. Over five years, JAZZ leads with a +64.3% price change compared with -7.4% for PRAX. Jazz Pharmaceuticals is the larger company by market cap ($14.40 billion vs $7.40 billion), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JAZZ | PRAX |
|---|---|---|
| Share price | $221.83 | $265.19 |
| Market cap | $14.40B | $7.40B |
| 1-day change | -4.05% | -4.61% |
| YTD return | +35.99% | -5.67% |
| 1-year return | +68.36% | +434.24% |
| 5-year return | +64.31% | -7.37% |
| P/E ratio (TTM) | 15.20 | — |
| Forward P/E | 8.56 | — |
| EPS (TTM) | $14.59 | $-12.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.27B | $0 |
| Revenue growth (YoY) | +4.88% | -100.00% |
| Net income (latest FY) | $-356.15M | $-303.27M |
| Operating margin | -10.08% | — |
| Net margin | -8.35% | — |
| 52-week high | $266.38 | $392.70 |
| 52-week low | $128.80 | $50.56 |
| Distance from 52-week high | -16.72% | -32.47% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +32.76% | +143.00% |
| Average volume | 850.55K | 403.18K |
| Shares outstanding | 64.91M | 27.92M |
| Employees | 2,890 | 168 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed JAZZ by 365.9 percentage points over the past year.
- Jazz Pharmaceuticals grew revenue faster in its latest fiscal year (+4.88% vs -100.00%).
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
JAZZ vs PRAX FAQ
Which is bigger, Jazz Pharmaceuticals or Praxis Precision Medicines?
Jazz Pharmaceuticals (JAZZ) is larger, with a market capitalization of $14.40B compared with $7.40B for Praxis Precision Medicines (PRAX).
Which stock has performed better over the past year, JAZZ or PRAX?
PRAX returned +434.24% over the past 12 months, compared with +68.36% for JAZZ (price return, excluding dividends). Past performance does not predict future results.
Are Jazz Pharmaceuticals and Praxis Precision Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.